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Summary
Primary lymphedema is a chronic tissue swelling, most
frequently of the lower limbs, resulting from deficient
lymphatic drainage. The variability of the affected phe-
notype, incomplete penetrance, lack of large families,
and possible genetic heterogeneity have hampered the
identification of causative genes until now. We carried
out a genomewide search, using a four-generationNorth
American family with dominantly inherited primary
congenital lymphedema (PCL), otherwise known as
“Milroy disease,” or “hereditary lymphedema type I”
(MIM 153100). Linkage to markers from the 5q35.3
region in this and four additional, British families was
established. A minimum of 79 directly scorable haplo-
types (37 affected) in five families conspicuously segre-
gated with the most telomeric region of 5q35.3, thus
suggesting a major locus for PCL in this vicinity. No
recombination was observed with D5S408 (Z  10.03)
and D5S2006 (Z  8.46) with a combined multipoint
score of 16.55. While D5S2073 and WIAF-2213 defined
the upper centromeric boundary, no recombinants were
obtained for the last telomeric marker of D5S2006. Four
unaffected subjects were identified as gene carriers and
provided an estimated penetrance ratio of .84 for this
condition. A few of the positionally mapped genes in
the 5q35 region that may potentially be involved in the
etiology of this condition are CANX, FGFR4, HK3, and
hnRPH1.
Introduction
Lymphedema is a chronic tissue swelling that is most
commonly manifested in a limb. This condition results
from impaired lymph drainage in the presence of normal
capillary filtration. It may be either primary in type,
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which implies an intrinsic abnormality of the lymph-
conducting pathways or, secondary in type, which im-
plies that external factors such as radiotherapy, severe
infection, or surgical excision have damaged lymph
drainage routes (Mortimer 1995a). The three main con-
sequences of lymphatic failure are swelling (lymphed-
ema), infection (cellulitis), and, very rarely, cancer (Mor-
timer 1995b).
Lymphedema may occur as part of a well-recognized
syndrome, in which the genetic defect may or may not
be known—for example, in Turner syndrome orNoonan
syndrome (Greenlee et al. 1993). Primary lymphedema
presents in a variety of clinical patterns, suggesting dif-
ferent underlying etiologies (Browse and Stewart 1985).
In the vast majority of families, the disease segregates in
an autosomal dominant fashion, as it does in the pig
model of congenital lymphedema (Van der Putte 1978).
The expression of lymphedema is sex influenced and is
much higher in females than in males, at 66% and 30%,
respectively (Dale 1985). Most forms of primary lym-
phedema are thought to be caused by a congenital ab-
normality of the lymphatic system; however, onset of
clinical symptoms in hereditary lymphedema type II
(MIM 153200) usually occurs during or near either pu-
berty or the menopause. True congenital lymphedema,
or hereditary lymphedema type I (MIM153100), usually
presents either at, or soon after, birth and may be as-
sociated with other congenital malformations, such as
distichiasis (Dale 1987; Kolin et al. 1991), congenital
heart disease (Corbett et al. 1982), and hydrocele (Irons
et al. 1996). Occasionally, primary lymphedema is both
congenital and familial. The first reports, by Nonne
(1891) and, in the following year, Milroy (1892), were
of families in which the edema was present at birth.
Herein we describe the localization of the first lym-
phedema locus and provide evidence that primary con-
genital lymphedema (PCL), also known as “Milroy dis-
ease” (MIM 153100), maps to the 5q35.3 region in one
large North American family and four British families.
Subjects and Methods
Ascertainment and Examination of Patients
During a 5-d period, 102 members (52 males and 50
females) of a single large four-generation North Amer-
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ican family of Irish descent (PCL-900; see fig. 1) were
clinically examined by a single experienced observer
(G.B.). A complete family history was obtained, and
photographs of deceased subjects were examined. The
clinical status of all examined affected subjects was doc-
umented. Diagnostic criteria included evidence of idio-
pathic, painless edema with characteristic skin thick-
ening and associated hyperkeratosis and papillomatosis.
Skin thickening was indicated by a positive Kaposi-Stem-
mer sign, which is a failure to pick up or pinch a fold
of skin at the base of the second toe (Stemmer 1976).
Twenty-milliliter EDTA blood samples, or buccal rub-
bings, were obtained from each individual, for DNA
extraction. All samples were taken with informed writ-
ten consent, either from the individual concerned or, in
the case of a child !18 years old, from a parent. The
study protocol and consent forms were approved by the
University of Connecticut Health Center institutional re-
view board. Skin biopsies and blood samples were also
obtained from two affected individuals, for cell culture
and karyotype analysis. A complete cytogenetic analysis
of these two subjects did not reveal any obvious chro-
mosomal abnormalities.
During the past 6 years, we have identified another
four PCL families, from Britain (fig. 2), consisting of
affected individuals in two (PCL-102), three (PCL-66
and PCL-100), or five (PCL-72) generations. DNA sam-
ples from a total of 17 affected (5 males and 12 females)
and 18 unaffected subjects (12 meioses) were available
for linkage study.
DNA and Linkage Study
DNA was extracted from peripheral blood and/or
buccal cells (DNAzol; Molecular Research Center [Cin-
cinnati] and Puregene), as described elsewhere (Moore
1994). A genomewide screen was performed with flu-
orescently end-labeled primers from the ABI Prism Link-
age Mapping Set consisting of chromosome-specific
marker loci selected from the linkage maps generated by
Ge´ne´thon (Weissenbach et al. 1992; Gyapay et al. 1994).
Saturation mapping was performed by use of additional
short tandem-repeat polymorphic (STRP) markers and
single-nucleotide polymorphisms (SNPs). Amplification
of the ABI Prism Linkage Mapping set was performed
in multiplex PCR reactions using primer concentrations
as suggested by the ABI manual. A total reaction volume
of 7.5 ml was used, consisting of 30 ng of genomic DNA,
buffer (10 mM Tris-HCl, pH 8.3, 50 mM1# PCR
KCl), 2.5 mM MgCl2, 250 mM of each dNTP, and 0.3
U of Taq polymerase (AmpliTaq Gold; Perkin-Elmer).
Amplifications were performed in a GeneAmp 9600
thermocycler (Perkin-Elmer), under the following con-
ditions: initial denaturation at 95C for 12min; 10 cycles
of denaturation at 94C for 15 s, annealing at 55C for
15 s (ramp time 2min from 94C to 55C), and extension
at 72C for 30 s; and an additional 20 cycles of dena-
turation at 89C for 15 s, annealing at 55C for 15 s
(ramp time 2 min from 89C to 55C), and extension at
72C for 30 s, followed by a final extension at 72C for
20 min. The amplified products were separated by elec-
trophoresis on the ABI-377 DNA Sequencer (Perkin-El-
mer), with GENESCAN (version 2.1) peak-calling soft-
ware (Perkin-Elmer). The alleles were scored by the
GENOTYPER (version 2.0) program (Perkin-Elmer).
Amplifications of chromosome 5–specific STRPmark-
ers were performed in a 25-ml reaction volume contain-
ing 100 ng of genomic DNA, 50 pmol of each primer,
210 mM of each dNTP, 50 mM KCl, 10 mM Tris-HCl
(pH 8.8), 1.5 mM MgCl2, 0.01% gelatin, and 0.5 U of
Taq polymerase (AmpliTaq; Perkin-Elmer). Amplifica-
tions were performed in a GeneAmp 9600 thermocycler
(Perkin-Elmer), under the following conditions: initial
denaturation at 94C for 2 min, 35 cycles of denatur-
ation at 94C for 15 s and annealing at 54C for 30 s,
and a final extension at 72C for 2 min. The amplified
products were separated by electrophoresis on 7% de-
naturing acrylamide gels, were visualized by silver stain-
ing (Bassam et al. 1991), and were photographed and
subsequently genotyped.
For the two SNP markers of WIAF-616 and WIAF-
2213 (Wang et al. 1998; WIBR/MITCGR Website), a
single-strand conformational polymorphism (SSCP)
assay was performed as follows: a 25-ml stop solution
containing 95% formamide, 20 mM EDTA, 0.05%
bromophenol blue, and 0.05% xylene cyanole was
added to the amplified fragments, and the reactions were
denatured at 94C for 5 min. Samples were run at room
temperature on a 10% polyacrylamide (acrylamide:bis-
acrylamide ratio 37.5:1), EDTA gels0.5# Tris-borate
at 9 W for 9 h, on a vertical electrophoresis unit (S2001)
with a cooling system (GIBCO BRL). The gels were
stained as described above. The exact sequence of the
observed SSCP variations was determined by direct se-
quencing of representative polymorphisms on an ABI-
377 DNA sequencer using dye-rhodamine chemistry. All
genotypes either from the ABI linkage mapping set, the
STRPs, or the two SNPs were entered into the Database
Management System program (M. Sarfarazi, unpub-
lished data) and subsequently were used to create data
files for analysis by the LINKAGE programs (Lathrop
and Lalouel 1984).
Results
Clinical Findings
A total of five families—one large North American
(fig. 1 ) and four British (fig. 2)—were used in this study.
The mode of inheritance in the North American family
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Figure 2 Pedigree structure of four PCL British families. The order of markers is shown. Haplotypes are denoted as in fig. 1. There are
no affected recombinations for any of the markers shown in these pedigrees. Note that in PCL-102 individual III:4 has inherited the affected
haplotype but is clinically unaffected.
was autosomal dominant, with no clinical evidence of
reduced penetrance or of sex-influenced expression. Be-
cause of the reported lack of full penetrance in the dom-
inant forms of congenital lymphedema (Milroy 1892),
members of generation IV who had unaffected parents
were also fully examined. Despite previously reported
associations of lymphedema with hypothyroidism (Jones
and Webb 1996), yellow nails (Wells 1966), and disti-
chiasis (Falls and Kertesz 1964), no such clinical man-
ifestations or other dysmorphic features were found. In
generation II, all 11 siblings were classified as affected,
on the basis of examination and/or history including
photographic evidence. There was no historical or pho-
tographic evidence that the mother of these 11 subjects
(individual I:2) was affected. However, her children re-
ported a history of recurrent leg infections in their father
(individual I:1), who was known within the family as
“piano legs.”
In this family, where presentation is invariably at
birth, the clinical diagnosis is relatively straightforward;
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Figure 3 A, Swelling of right foot, since birth, in a 6-year-old child (fig. 1, individual IV:8). B, Marked swelling, with papillomatosis and
nail changes, in a 70-year-old man (fig. 1, individual II:1). C, Bilateral swelling, since birth, in a 45-year-old man (fig. 1, individual III:1). D,
Right foot of individual III:1, immediately after removal of compression hosiery, demonstrating papillomatosis.
however, there is marked variation in the degree of ex-
pression within the family. For example, congenital
swelling of the right foot in a 6-year-old subject (fig. 1,
individual IV:8) is illustrated in figure 3A.Marked swell-
ing together with papillomatosis and nail changes in the
left foot of a 70-year-old man (fig. 1, individual II:11)
is shown in figure 3B.Asymmetrical bilateral leg swelling
that has been present since birth in a 45-year-old in-
dividual (fig. 1, individual III:1) is presented in figure
3C. The right foot of the same subject (individual
III:1), which is shown in figure 3D, demonstrates
papillomatosis.
Eight of the affected family members gave a history
of either fungal or bacterial infections, with one report
that amputation of the foot had been suggested during
the course of a particularly severe infection. This advice
was rejected, and the limb eventually responded to an-
tibiotic therapy. Three members of the family had un-
dergone investigations using Evans blue dye injected into
the subcutaneous tissues of the foot. Both individual II:
13 and individual III:38 still had evidence of residual
blue dye after 9 mo. Deceased individual II:5 also
underwent radio-contrast lymphangiography, showing
aplasia of lymphatic glands. All affected individuals re-
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Table 1
Combined LOD-Score Values, for Five PCL Families and Seven Polymorphic DNA Markers
from the 5q35.3 Region
MARKER
Z AT v  Zmax (vmax) IN
.00 .05 .10 .20 .30 .40 All Meioses Affected Meioses
D5S2030  .48 2.49 3.31 2.67 1.35 3.31 (.19) 1.21 (.20)
WIAF-616  2.65 3.10 2.47 1.34 .46 3.10 (.10) .09 (.37)
D5S2073  7.01 6.63 5.14 3.37 1.54 7.01 (.05) 1.51 (.07)
WIAF-2213  9.46 8.96 7.24 5.08 2.58 9.49 (.04) 1.34 (.11)
D5S1354 7.09 6.31 5.53 3.99 2.52 1.18 7.09 (.00) 2.72 (.00)
D5S408 10.03 9.80 8.96 6.94 4.70 2.32 10.03 (.00) 5.27 (.00)
D5S2006 8.46 8.00 7.24 5.35 3.28 1.31 8.46 (.00) 4.33 (.00)
ported that swelling had been present since birth and
that the distribution had not altered with time; thus,
those mildly affected at birth remained so throughout
life. The degree to which individuals were affected
ranged from single toes to the complete leg; however,
there was no evidence of edema in hands, face, trunk,
or sacrum. In 4 of the 19 affected individuals lymphed-
ema was unilateral, and in 7 others the swelling was
bilateral but asymmetrical in distribution, with the re-
maining 8 individuals being affected equally bilaterally.
Severe papillomatosis was present in five individuals
(four males and one female), with one giving a history
of successful surgical removal of the growths 30 years
previously. The Kaposi-Stemmer sign was positive in 15
of 19 affected individuals but in none of the unaffected
family members. The presence of edema, which subsides
readily with overnight elevation, suggests that the prob-
lem lies in excessive capillary filtration, rather than in
reduced lymphatic drainage. Of 19 affected subjects, 10
reported that the swelling was not significantly reduced
by overnight elevation of the limb whereas 9 reported
varying degrees of incomplete reduction of swelling. Sev-
eral individuals wore compression stockings, whichwere
effective in containing the edema, whereas those who
were more severely affected attended hospital for com-
pression pumping to reduce limb size prior to being fit-
ting for compression hosiery.
Four white English families with congenital lymphed-
ema were also referred by interested clinicians, for link-
age studies (fig. 2). Pedigree analysis showed no evidence
of skipped generations; however, in two families (PCL-
72 and PCL-66) males were less severely affected than
females. Involvement in affected individuals ranged from
swelling of only the toes to swelling of the entire leg.
Five patients suffered unilateral lower-leg involvement
only. There were no reports or evidence of edema other
than that in the lower limbs. One individual (individual
III:7 in PCL-66) had undergone attempted bilateral
pedal lymphangiograms and bilateral inguinal lymphan-
giograms. Patent blue dye was injected into the webs of
the feet. Exploratory incisions were made on the dorsum
of each foot. No lymphatic vessels were located by either
method. The groins were explored, and lymphangio-
grams were performed, which showed almost normal
lymph vessels and nodes in the groin and in the iliac and
lumbar regions. The diagnosis of peripheral lymphatic
aplasia was made, and the patient was treated
conservatively.
Linkage Analysis
For the purpose of positional mapping, we selected a
group of 32 (21 affected individuals and their spouses
and 4 normal subjects) from the North American family
and scanned the genome randomly with the ABI Prism
Linkage Mapping Set. Once a suggestion of linkage was
found with the DNA markers D5S429 and D5S408,
samples from 25 affected and 32 unaffected subjects
were used for saturation mapping (fig. 1). An additional
11 markers from this region, including two new SNP
markers (Wang et al. 1998), were used to genotype and
construct the inherited haplotype in this kindred. As
shown in figure 1, a total of 57 directly scorable meioses
(25 affected individuals) conspicuously segregated with
the three most telomeric markers. Inspection of haplo-
types indicated that the gene for this kindred maps telo-
meric to the SNP marker WIAF-2213. Since the affected
subject II:15 is not informative for D5S1354 and
D5S408, neither the precise site of recombination in his
children (individuals III:40 and III:44) nor the exact lo-
cation of this SNP marker in relation to these two mark-
ers can be determined. However, both genetic-linkage
mapping and radiation mapping data show that
D5S1354 and WIAF-2213 are tightly linked to D5S408.
In addition, our radiation mapping data for D5S2006
(not shown), as well as the published linkage data,
clearly show that this marker is telomeric to both
D5S408 and all other markers used in this study. The
absence of recombination with marker D5S2006 in af-
fected subject II:15 suggests that the newly identified
PCL locus is tightly linked to this marker.
To test for genetic heterogeneity, we used four British
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Table 2
Three-Point Linkage Scores, for PCL Phenotype (in One American Family and Four British
Families) and Combined Haplotypes of D5S408 and D5S2006, in All Meioses
SOURCE
Z AT v 
.00 .05 .10 .15 .20 .25 .30 .35 .40 .45
American 12.61 12.01 11.05 9.95 8.74 7.45 6.06 4.59 3.03 1.40
British 3.94 3.90 3.58 3.16 2.70 2.21 1.72 1.24 .79 .38
Combined 16.55 15.91 14.63 13.11 11.44 9.66 7.78 5.83 3.82 1.78
families with congenital lymphedema and established
tight linkage in all families studied. No recombination
was observed in the British families with any of the seven
DNAmarkers genotyped (fig. 2). Table 1 shows the com-
bined LOD score (Z) values for all five PCL families and
seven DNAmarkers from the 5q35.3 region. The overall
three-point scores for linkage between PCL and two
DNA markers—D5S408 and D5S2006—are presented
in table 2, for the North American family and for the
four British families. There is overwhelming evidence for
localization of the PCL locus to this region, with Z val-
ues of 3.10–10.03 for individual markers (table 1), as
well as a combined haplotype score of 16.55 for the last
two DNA markers, D5S408 and D5S2006 (table 2).
Since, in the literature, there is evidence for incomplete
penetrance in this condition (Dale 1985), we repeated
the Z analysis for affected meioses only. Although the
Z values decreased (table 1), they remained statistically
significant, ranging from 5.27 (for D5S408) and 4.33
(for D5S2006) to 8.76 (for the haplotype of the two
markers).
All clinically affected subjects within a family shared
a common haplotype. Of the 44 clinically unaffected
subjects genotyped, 4 males had also inherited the af-
fected haplotype. Three of these individuals, ages 46, 7,
and 9 years, respectively, belong to PCL-900 (fig. 1, in-
dividuals III:23, IV:5, and IV:7), and the fourth, age 5
years, belongs to PCL-102 (fig. 2, individual III:4). The
three youngest individuals had no clinical signs of being
affected, whereas individual III:23 demonstrated mild
pedal edema and, in common with seven other examined
affected male family members, reported a history of hy-
drocele. It is likely that these four males represent either
incomplete or age-dependent penetrance, consistentwith
the previously reported low penetrance in males com-
pared with females (Dale 1985). For the purpose of link-
age analysis (tables 1 and 2), the clinical status of these
four subjects was coded as “unknown.”
Once linkage of PCL to the 5q35.3 region had been
established, an estimate of penetrance was calculated for
this phenotype. Three liability classes were defined—one
for spouses, one for affected subjects, and one for
at-risk individuals. Since DNA markers in different
branches of these pedigrees were noninformative, we
used a three-point multipoint score, between the PCL
phenotype and the haplotype of D5S408 and D5S2006,
to maximize the linkage information. The penetrance
ratios for the at-risk individuals were .5–1.0, and their
corresponding three-point scores were calculated. This
analysis resulted in a maximum Z (Zmax) of 13.39 at a
ratio of .16 (penetrance ratio .84).
Discussion
The findings reported in this paper indicate that the
first locus for primary congenital lymphedema has been
identified. Heterogeneity for the primary lymphedemas
is probable because of both the variable age at onset
and the differing clinical and lymphoscintigraphy find-
ings in families with congenital, juvenile, and adult-onset
lymphedema. In this study we used a four-generation
North American family with PCL and mapped a locus
to the 5q35.3 region. Three generations of this family
had been examined almost 35 years ago (Beninson et al.
1967; Klemmer et al. 1997), at which time it was stated
that 22 members of the F2 generation showed signs con-
sistent with either obvious lymphedema or lymphatic
dysplasia without clinical signs. Lymphatic dysplasia
was diagnosed solely on the basis of the palpable thick-
ening of the skin on the extremities. It is therefore note-
worthy that, in our study, there are nine individuals in
whom the clinical classification has changed from that
in the originally published pedigree. In view of our clin-
ical examination during 1998, it is apparent that none
of those individuals originally thought to have lymphatic
dysplasia have progressed to develop lymphedema, de-
spite the passage of 34 years. This underlines the need
for a simple diagnostic test, now available to this family
as a result of our linkage study. Five of the nine indi-
viduals in whom there is a discrepancy have, among
them, eight offspring. None of these offspring show any
signs of lymphedema, which strengthens our clinical im-
pression that their parents are unaffected. Although it
is possible that those originally described as having lym-
phatic dysplasia may still develop lymphedema, there is
no precedent for it in this large pedigree, where, to date,
presentation invariably has been at birth. One interesting
feature in this family is that all 11 siblings in generation
II were affected. A possible explanation for this is that
the father of these 11 individuals (individual I:1) was
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affected as a result of a rare new mutation during the
preembryonic period, such that all his spermatogonia
carried the mutation, resulting in a single population of
mutation-bearing sperm. An alternative explanation—
that he was homozygous for the disease gene—is less
likely, in view of his mild clinical signs.
The genetic linkage that was seen in this North Amer-
ican PCL family was subsequently confirmed in four
British families. Taken together, these five families pro-
vide substantial evidence for localization of the PCL lo-
cus to 5q35.3. We observed no recombination with ei-
ther D5S408 ( ), D5S2006 ( ), or theirZ  10.03 Z  8.46
combined multipoint haplotype ( ).When onlyZ  16.55
the affected meioses were used in the analysis, Z values
of 5.27 (D5S408), 4.33 (D5S2006), and 8.76 (for the
haplotype of D5S408 and D5S2006) were obtained. We
also used two newly described SNP markers from this
region (Wang et al. 1998), both of which showed re-
combination in the affected subjects (fig. 1) and which
therefore are outside the critical region of PCL.However,
the closer SNP marker WIAF-2213 was sufficiently in-
formative to yield at recombination fractionZ  9.49max
(v) of .04 (table 1). This observation confirms the use-
fulness of this new type of polymorphism in mapping
studies (Wang et al. 1998). Once linkage to this region
had been established, we used a total of 44 normal mei-
oses in these pedigrees and estimated a penetrance ratio
of .84 for this condition. Construction and inspection
of the inherited haplotypes (fig. 1) in theNorthAmerican
family confirmed that the PCL locus is flanked by two
centromeric markers—D5S2073 and WIAF-2213—but
no corresponding telomeric flanking marker has been
identified. There is no recombination with D5S2006, the
most telomeric known polymorphic marker in this re-
gion. Therefore, it is possible that PCL maps telomeric
to all of the known existing markers. There is an obvious
need for both development of additional polymorphic
markers and establishment of a closely flanking marker,
before any attempts can be made to clone the putative
PCL gene.
The human-transcript map at the GeneMap’98 Web-
site of the National Center for Biotechnology Infor-
mation currently lists the gene for calnexin (CANX), the
gene for EBI3-associated protein-p60, and 23 other ex-
pressed sequence tags that map between D5S408 and
D5S2006. Other genes that loosely map to the 5q35
region are NPM1 (for nucleophomin), SNCB (for syn-
uclein beta), GPRK6 (for G protein–coupled receptor
kinase 6), FGFR4 (for fibroblast growth-factor receptor
4), LTC4S (for leukotriene C4 synthases),HK3 (for hex-
okinase 3), and hnRPH1 (for heterogeneous nuclear ri-
bonucleoprotein H1). The precise mapping of these
genes in relation to D5S408 and D5S2006, as well as
their possible role in the etiology of primary congenital
lymphedema, remains to be determined.
Although no obvious candidate gene for protein com-
ponents of the lymphatic wall maps to the 5q35.3 region,
other possible modifying genes mapping to this or other
regions may explain the reduced penetrance seen in some
family members (Witte 1997). Linkage studies involving
other families with congenital, juvenile, and adult-onset
lymphedema will test for genetic heterogeneity and may
provide evidence for phenotype-genotype correlation.
The phenotype studied here is deforming, with asso-
ciated psychological as well as medical problems, all of
which are treatable (Mortimer 1995a; 1995b). Pre-
symptomatic screening of all at-risk first-degree relatives
would be desirable to prevent complications, by early
advice and treatment. Once identified as gene carriers,
individuals at risk can be kept under regular surveillance
and can be advised to (a) avoid infection, by maintaining
strict hygiene of the feet, with early attention to fungal
or bacterial infections; (b) avoid excessive weight gain;
(c) exercise regularly; (d) use manual lymphatic drainage
and either support hose or bandaging; and (e) avoid
occupations that require standing for long periods. Such
individuals may be at increased risk of lymphedema after
surgery or irradiation (Tobin et al. 1993). Better treat-
ment, based on improved understanding of the under-
lying molecular defect, is urgently required for this
disease.
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